AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17269368 — intervention group
Group type: COMPARATOR
Intervention: Seasonal allergic rhinitis patients
Number of subjects: 42
Study 17269368 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 42
Study 15643684 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant LH supplementation
Number of subjects: 0
Study 15643684 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist
Number of subjects: 0
Study 11584994 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for primary and secondary prevention of toxoplasmosis
Number of subjects: 0
Study 11584994 — intervention group
Group type: COMPARATOR
Intervention: Screening of seronegative pregnant women
Number of subjects: 0
Study 9042993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg three times daily)
Number of subjects: 121
Study 9042993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 9042993 — intervention group
Group type: COMPARATOR
Intervention: Cisapride and Placebo
Number of subjects: 121
Study 8003313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 0
Study 8003313 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 2955672 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (DOX), 10.8 mg daily
Number of subjects: 115
Study 2955672 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ), 89.1 mg daily
Number of subjects: 115
Study 2955672 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (DOX)
Number of subjects: 115
Study 2955672 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 115
Study 31375459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryolipolysis (one session at -10°C for 50 minutes)
Number of subjects: 34
Study 31375459 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study 29073323 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot (Nac‐)5‐ASA urinalysis by HPLC
Number of subjects: 29
Study 26614120 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute one-legged exercise
Number of subjects: 0
Study 26614120 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin stimulation after acute exercise
Number of subjects: 0
Study 26614120 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weeks of one-legged exercise training
Number of subjects: 0
Study 23772874 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (CYP3A probe) administered to patients with severe liver cirrhosis (CP C)
Number of subjects: 30
Study 23772874 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (CYP3A probe) administered to patients with moderate liver cirrhosis (CP B)
Number of subjects: 30
Study 23772874 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without liver disease)
Number of subjects: 30
Study 23772874 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Child-Pugh and MELD scores with unbound midazolam clearance
Number of subjects: 30
Study 21883386 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 10mg, four doses daily, at 4h intervals
Number of subjects: 24
Study 21883386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200mg 12‐hourly
Number of subjects: 24
Study 21883386 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone and ketoconazole together
Number of subjects: 24
Study 21883386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21189775 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz appliance treatment (expanded group)
Number of subjects: 28
Study 21189775 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-expanded)
Number of subjects: 28
Study 18672634 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylorus-preserving pancreaticoduodenectomy (PPPD)
Number of subjects: 27
Study 18672634 — intervention group
Group type: COMPARATOR
Intervention: Standard whipple operation (SW)
Number of subjects: 27
Study 15983525 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-specific (modified low fat including 30 g walnuts/day)
Number of subjects: 55
Study 15983525 — intervention group
Group type: COMPARATOR
Intervention: Modified low-fat (total diet advice using exchange lists to differentiate PUFA-rich foods)
Number of subjects: 55
Study 15983525 — intervention group
Group type: COMPARATOR
Intervention: Low-fat (general advice)
Number of subjects: 55
Study 12463724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) administration of almotriptan (3 mg)
Number of subjects: 18
Study 12463724 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) administration of almotriptan (6 mg)
Number of subjects: 18
Study 12463724 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of almotriptan (25 mg)
Number of subjects: 18
Study 11783210 — intervention group
Group type: EXPERIMENTAL
Intervention: Gubiyin (GBY)
Number of subjects: 70
Study 11783210 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (control)
Number of subjects: 70
Study 7540696 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (5 micrograms/kg body weight per day)
Number of subjects: 121
Study 7540696 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (5 micrograms/kg body weight per day)
Number of subjects: 121
Study 7540696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 7540696 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 121
Study 7540696 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 121
Study 1835930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms, three times a day for 2 weeks)
Number of subjects: 12
Study 1835930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 726859 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbiturates (pentobarbital premedication and thiopental induction)
Number of subjects: 28
Study 726859 — intervention group
Group type: COMPARATOR
Intervention: Control group (halothane and nitrous oxide only)
Number of subjects: 28
Study 30674486 — intervention group
Group type: EXPERIMENTAL
Intervention: Community randomised trial intervention to improve school hearing screening and referral process, details on dosage and duration not specified.
Number of subjects: 15
Study 30674486 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative and mixed methods components including focus groups and community events.
Number of subjects: 15
Study 30674486 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder interviews with parents, children, teachers, school administrators, and community health aides.
Number of subjects: 15
Study 30674486 — intervention group
Group type: EXPERIMENTAL
Intervention: Concluding focus groups with policymakers, healthcare administrators, and community leaders.
Number of subjects: 15
Study 27988806 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine hydrochloride (strong centrally acting anticholinergic)
Number of subjects: 22
Study 27988806 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine hydrobromide (moderate centrally acting anticholinergic)
Number of subjects: 22
Study 27988806 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide (anticholinergic devoid of central properties)
Number of subjects: 22
Study 27988806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 26181658 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedratinib 400 mg
Number of subjects: 289
Study 26181658 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedratinib 500 mg
Number of subjects: 289
Study 26181658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 23497838 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group intervention
Number of subjects: 382
Study 23497838 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 382
Study 21530875 — intervention group
Group type: EXPERIMENTAL
Intervention: European Bermuda grass extract
Number of subjects: 6
Study 21530875 — intervention group
Group type: EXPERIMENTAL
Intervention: European cat extract
Number of subjects: 6
Study 21530875 — intervention group
Group type: COMPARATOR
Intervention: US FDA reference extract
Number of subjects: 6
Study 18533155 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational toolbox intervention
Number of subjects: 2
Study 18533155 — intervention group
Group type: COMPARATOR
Intervention: Reference organization (no toolbox)
Number of subjects: 2
Study 17243195 — intervention group
Group type: EXPERIMENTAL
Intervention: OD1 (20 mg once daily with a 1-step up-titration)
Number of subjects: 78
Study 17243195 — intervention group
Group type: EXPERIMENTAL
Intervention: OD3 (20 mg once daily with a 3-step up-titration)
Number of subjects: 78
Study 17243195 — intervention group
Group type: EXPERIMENTAL
Intervention: BID3 (10 mg twice daily with a 3-step up-titration)
Number of subjects: 78
Study 15071282 — intervention group
Group type: EXPERIMENTAL
Intervention: Virosome-adjuvanted influenza vaccine
Number of subjects: 453
Study 15071282 — intervention group
Group type: COMPARATOR
Intervention: Split influenza vaccine
Number of subjects: 453
Study 11679510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer
Number of subjects: 800
Study 11679510 — intervention group
Group type: COMPARATOR
Intervention: Clinical touch method
Number of subjects: 800
Study 9629991 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranid (300 mg)
Number of subjects: 24
Study 9629991 — intervention group
Group type: COMPARATOR
Intervention: Zantac (300 mg)
Number of subjects: 24
Study 8159781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (30 ml in 100 ml physiological saline i.v. once a day from Monday to Friday for four weeks)
Number of subjects: 120
Study 8159781 — intervention group
Group type: COMPARATOR
Intervention: Placebo (130 ml physiological saline)
Number of subjects: 120
Study 3124685 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH insulin
Number of subjects: 31
Study 3124685 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 31
Study 31435732 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pyeloplasty (LP)
Number of subjects: 53
Study 31435732 — intervention group
Group type: COMPARATOR
Intervention: Robotic-assisted laparoscopic pyeloplasty (RALP)
Number of subjects: 53
Study 29399852 — intervention group
Group type: EXPERIMENTAL
Intervention: Task analysis‐based training (small-group session and e-learning)
Number of subjects: 124
Study 29399852 — intervention group
Group type: COMPARATOR
Intervention: Usual educational approach (Control)
Number of subjects: 124
Study 28932907 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 45
Study 28932907 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Training (CT)
Number of subjects: 45
Study 28932907 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 45
Study 26577969 — intervention group
Group type: EXPERIMENTAL
Intervention: Camel milk therapy for 2 weeks
Number of subjects: 65
Study 26577969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 22993051 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogic breathing exercise (YBG)
Number of subjects: 96
Study 22993051 — intervention group
Group type: COMPARATOR
Intervention: Video control (VCG)
Number of subjects: 96
Study 21575465 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedaplatin plus 5‐fluorouracil (NF group)
Number of subjects: 100
Study 21575465 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus 5‐fluorouracil (PF group)
Number of subjects: 100
Study 18457800 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff willingness to facilitate research
Number of subjects: 682
Study 18457800 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility characteristics
Number of subjects: 682
Study 18457800 — intervention group
Group type: EXPERIMENTAL
Intervention: Function measures (Late Life FDI scale, timed-up-and-go, FICSIT balance scale, Elderly Mobility Scale)
Number of subjects: 682
Study 18457800 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life measures (EuroQol quality of life scale, Life Satisfaction Index)
Number of subjects: 682
Study 18457800 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls assessment (audit of the medical record)
Number of subjects: 682
Study 17031505 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuric group
Number of subjects: 40
Study 17031505 — intervention group
Group type: COMPARATOR
Intervention: Normoalbuminuric group
Number of subjects: 40
Study 14979753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervening treatment with varying number of memory retrievals
Number of subjects: 7
Study 14979753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervening treatment with time allowed for memory retrievals
Number of subjects: 7
Study 11681505 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with mitomycin-C (0.4 mg/ml for 2.5 min)
Number of subjects: 22
Study 11681505 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy alone (Control)
Number of subjects: 22
Study 9444745 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluconazole (100 mg followed by 50 mg/day for 14 days) with catheter replacement
Number of subjects: 30
Study 9444745 — intervention group
Group type: COMPARATOR
Intervention: Catheter replacement alone
Number of subjects: 30
Study 7625301 — intervention group
Group type: EXPERIMENTAL
Intervention: clemastine (2mg orally)
Number of subjects: 11
Study 7625301 — intervention group
Group type: EXPERIMENTAL
Intervention: mepyramine (2 micrograms intradermally)
Number of subjects: 11
Study 7625301 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 2893930 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 2893930 — intervention group
Group type: COMPARATOR
Intervention: Lofexidine
Number of subjects: 0
Study 30616613 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral polyherbal dietary supplement (GlucoSupreme™ Herbal) for 12 weeks
Number of subjects: 40
Study 30616613 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 40
Study 25760154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled group (7 subjects) immersed forearms in cold water (10±1°C) for 20 min after exercises
Number of subjects: 14
Study 25760154 — intervention group
Group type: COMPARATOR
Intervention: Noncooled group (7 subjects)
Number of subjects: 14
Study 24284309 — intervention group
Group type: EXPERIMENTAL
Intervention: HI-SPI (SPI > 50)
Number of subjects: 42
Study 24284309 — intervention group
Group type: EXPERIMENTAL
Intervention: LO-SPI (SPI < 50)
Number of subjects: 42
Study 24284309 — intervention group
Group type: COMPARATOR
Intervention: Both HI-SPI and LO-SPI
Number of subjects: 42
Study 22763424 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions
Number of subjects: 810
Study 19568715 — intervention group
Group type: EXPERIMENTAL
Intervention: TXYF granule, one package twice a day for 4 weeks
Number of subjects: 120
Study 19568715 — intervention group
Group type: COMPARATOR
Intervention: Miyarisan, two tablets three times a day for 4 weeks
Number of subjects: 120
Study 19568715 — intervention group
Group type: EXPERIMENTAL
Intervention: TXYF granule
Number of subjects: 120
Study 17703830 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 210
Study 17703830 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 210
Study 16167226 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper abdomen median incision
Number of subjects: 63
Study 16167226 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined left thoracotomy and abdomen incision
Number of subjects: 63
Study 16167226 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined viscera excision
Number of subjects: 63
Study 16167226 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical resection
Number of subjects: 63
Study 16167226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node metastasis
Number of subjects: 63
Study 16167226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node metastasis involving abdominal cavity
Number of subjects: 63
Study 16167226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node metastasis involving thoracic cavity
Number of subjects: 63
Study 12399622 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (PGI(2))
Number of subjects: 27
Study 12399622 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 9697724 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 (N-9) gel applied daily for 2 weeks
Number of subjects: 0
Study 11271222 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 545
Study 11271222 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A (CsA)
Number of subjects: 545
Study 11271222 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506 and CBIR
Number of subjects: 545
Study 3176107 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard one‐compartmental model calculations after a single dose of theophylline syrup (mean dose 413 mg)
Number of subjects: 33
Study 3176107 — intervention group
Group type: EXPERIMENTAL
Intervention: Low theophylline dosage regimen (twice daily)
Number of subjects: 33
Study 3176107 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium theophylline dosage regimen (twice daily)
Number of subjects: 33
Study 3176107 — intervention group
Group type: EXPERIMENTAL
Intervention: High theophylline dosage regimen (twice daily)
Number of subjects: 33
Study 3176107 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian analysis
Number of subjects: 33
Study 3176107 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug nomogram
Number of subjects: 33
Study 3176107 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2‐month duration)
Number of subjects: 33
Study 31158271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (q12w)
Number of subjects: 567
Study 31158271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (q8w)
Number of subjects: 567
Study 31158271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (overall)
Number of subjects: 567
Study 29986347 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based psychological counselling service
Number of subjects: 0
Study 28299001 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol 0.5%
Number of subjects: 62
Study 28299001 — intervention group
Group type: COMPARATOR
Intervention: Fluorometholone 0.1%
Number of subjects: 62
Study 25733274 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (3 years treatment)
Number of subjects: 670
Study 23742033 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (5 Gy x 5) followed by full-dose chemotherapy (capecitabine and oxaliplatin) in 6 cycles before surgery
Number of subjects: 0
Study 23742033 — intervention group
Group type: COMPARATOR
Intervention: Standard arm: chemoradiation (1.8 Gy x 25 or 2 Gy x 25 with capecitabine) preoperatively, followed by selective postoperative adjuvant chemotherapy (optional)
Number of subjects: 0
Study 21967987 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine D(2/3) receptor agonist (pramipexole, 0.5 mg)
Number of subjects: 18
Study 21967987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21967987 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine D(2/3) receptor antagonist (amisulpride, 400 mg)
Number of subjects: 18
Study 18430206 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no intervention was tested)
Number of subjects: 636
Study 16390899 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement program (medication)
Number of subjects: 1356
Study 16390899 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement program (therapy)
Number of subjects: 1356
Study 16390899 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1356
Study 16390899 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement program (medication/therapy)
Number of subjects: 1356
Study 14657758 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP given OW (4 mg/kg from birth to 14 days, upward arrow to 8 mg/kg from 15 days to 24 weeks)
Number of subjects: 75
Study 14657758 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP given TW (4 mg/kg from birth to 14 days, upward arrow to 8 mg/kg from 15 days to 24 weeks)
Number of subjects: 75
Study 14657758 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP given OD (2 mg/kg from birth to 14 days, upward arrow to 4 mg/kg from 15 days to 24 weeks)
Number of subjects: 75
Study 10992173 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg 17beta‐estradiol + 25 microg gestodene (group 2/25s)
Number of subjects: 278
Study 10992173 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol + 50 microg gestodene (group 2/50s)
Number of subjects: 278
Study 10992173 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol + 25 microg gestodene (group 1/25s)
Number of subjects: 278
Study 10992173 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol + 25 mg gestodene (group 1/25c)
Number of subjects: 278
Study 10992173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 9238726 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy three times a week for 5 weeks
Number of subjects: 34
Study 9238726 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 34
Study 1361068 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 100 micrograms twice daily
Number of subjects: 350
Study 1361068 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 micrograms twice daily
Number of subjects: 350
Study 6365965 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysis-centrifugation system processed within 9 hours
Number of subjects: 5125
Study 6365965 — intervention group
Group type: COMPARATOR
Intervention: Lysis-centrifugation system processed after 9 hours
Number of subjects: 5125
Study 30355209 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 642
Study 30355209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642